We view our enviable positioning in medical cannabis as a tailwind that over time will translate into success on a global scale. First, let me say by talking about our domestic medical cannabis business, complete overview which is on very solid ground, we’re number one by revenue in Canada’s medical market, which as you know, is the largest federally regulated medical market in the world. And our estimated market share is nearly double that of our next largest competitor. And while we believe that Aurora is the largest Canadian pure-play cannabis LP in the market has an incredible opportunity within the global cannabis space. Aurora Cannabis, informative post Inc. To see find out more information regarding find out more visit our own web-site. (NYSE: ACB) on Thursday reported a narrower net loss for the second quarter of 2022. The company’s revenues dropped 10% year-over-year during the quarter. Greetings and welcome to the Aurora Cannabis, Inc. Third Quarter 2021 Results Conference Call. Aurora Cannabis Inc. (NYSE: complete overview ACB) Q3 2021 earnings call dated May.
With that, useful guide I would like to turn the call over to Miguel. "During the second quarter, we improved our Adjusted EBITDA by $2.5 million over Q1, moving us closer to our profitability goal. Also, the company reiterated its previous estimates of achieving sustained EBITDA positive results from the second calendar quarter of this year to fiscal Q4. Adjusted EBITDA loss was C$9 million, compared to C$11.2 million last year. This condition most commonly arises from marked weight loss that reduces the size of the fat pad between these vessels, causing greater acuity of angulation. For the second quarter, Aurora Cannabis slipped to a loss from a profit last year, due to higher costs and expenses. Taking this point one step further, as of March 31st, Aurora was the second-largest trading LP in terms of global cannabis sales and a leader across multiple markets and segments. Further, we continued our civic success, leveraging these core capabilities from Canadian medical into our growing international medical platform. The domestic medical business is unique as it represents a direct-to-patient distribution model that is powered by sophisticated technology infrastructure, allowing for an end-to-end patient experience.
The first paper is a paper detailing Israeli experience with treating children with treatment resistant epilepsy with medical cannabis oil. This high-touch approach to the medical channel is unique and is not easily replicated in the adult-use retail experience. We are extremely proud of the investment in technology and infrastructure we’ve made to service the medical patient base and it provides a tangible barrier to entry to the medical channel. The dispensary offers a diverse selection of strains, accommodating the needs of a varied customer base. Eden Rodriguez was the first customer to enter Lethbridge’s first retail marijuana store - and he left to cheers from the crowd still waiting to enter NewLeaf Cannabis. The first nine were charged under provincial law, while the rest were charged federally under the Cannabis Act, she said. In an adult-use environment, with low barriers entry, and provincial middlemen adding a layer of cost and complexity, the Canadian medical channel’s direct-to-patient model is a welcome, sustainable, high-margin diversification piece to Aurora’s business. And we continue to believe that this expertise represents a key success factor for Aurora as new countries look at launching medical cannabis regimes. Companies with success operating in federally regulated medical systems like those governed by Health Canada or the German health ministry are going to be an advantage for new markets open up to federal regulations, typically first for medical then for recreational adult use.
In a country like the United States and their federally regulated system, we would fully expect the FDA to have significant influence in the federal medical cannabis program. However, anecdotal feedback from veterans shows that VA’s directives and actual patient experiences sometimes differ in cases where a prescribed medical marijuana user walks into a federal (VA) facility. Revenue soared 363% helped by a jump in medical cannabis revenue. "Jumal had always made it clear that he intended to work in the legal cannabis market and he took the steps to do that," said his former colleague Hassell. I think it is clear from our results that Aurora benefits greatly in how we built a diversified business across domestic medical, international medical, and adult-use recreational markets. Notably, our international medical business also thrived during the period, demonstrating sequential growth even as many of our peers experienced declines. I’d like to start with some brief thoughts on the quarter including a discussion of our domestic and international medical businesses and then I’ll address our plans for the near-term challenges in the Canadian adult-use business.